Invivyd, Inc. is a biotechnology company focused on developing innovative therapies to address significant unmet medical needs in the field of infectious diseases. The company primarily concentrates on creating monoclonal antibody treatments designed to prevent and treat viral infections, thereby aiming to improve patient outcomes and enhance public health. With a commitment to leveraging cutting-edge research and development, Invivyd seeks to bring new and effective solutions to the market, ultimately striving to protect populations from the impact of various viral threats. Read More
Billionaire hedge fund manager Steven Cohen is diving into small-cap biotech with new stakes in two clinical-stage companies, signaling confidence in their potential for outsized returns.
Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will present at the following investor conferences:
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
Power Metallic Mines Inc. (TSX-V: PNPN; OTCQB: PNPNF; Frankfurt: IVV) today announced the appointment of Seamus O’Regan Jr., Canada’s former Minister of Energy & Natural Resources, to its Board of Directors.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the closing of its previously announced underwritten public offering of 89,234,480 shares of its common stock, which includes the exercise in full by the underwriter of its option to purchase an additional 14,423,076 shares of common stock, at a public offering price of $0.52 per share and pre-funded warrants to purchase 21,342,442 shares of its common stock at a public offering price of $0.5199 per pre-funded warrant, which represents the per share price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. All of the shares and pre-funded warrants were offered by Invivyd. The gross proceeds from this offering were approximately $57.5 million, before deducting underwriting discounts and commissions and offering expenses payable by Invivyd.
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
WALTHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 74,811,404 shares of its common stock at an offering price of $0.52 per share and, to certain investors, in lieu of common stock, pre-funded warrants to purchase 21,342,442 shares of its common stock at a price of $0.5199 per pre-funded warrant. The gross proceeds from this offering are expected to be approximately $50.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Invivyd. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, minus the $0.0001 per share exercise price of each such pre-funded warrant. All of the shares and pre-funded warrants are being offered by Invivyd. In addition, Invivyd has granted the underwriters an option for a period of 30 days to purchase up to an additional 14,423,076 shares of Invivyd common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about August 22, 2025, subject to the satisfaction of customary closing conditions.
